Clinical trial · Interventional
Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer
NCT03867045CI-TRIAL-00052245Cabo AppterminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study deemed non-essential under COVID pandemic,
Summary
Brief summary (as posted)
The purpose of this study is to develop an on-line electronic symptom management application that can ultimately be used to improve clinical outcomes in patients with mRCC treated with cabozantinib.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Renal Cell Carcinoma Treated With Cabozantinib | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Usability of an electronic symptom management application | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- mRCC treated with cabozantinib
- description
- Nine patients with mRCC initiating cabozantinib therapy who meet subject eligibility criteria.
- interventionNames
- Device: Usability of an electronic symptom management application
Primary outcomes (1)
- measure
- Number of comments from participants indicating ease of use of the application.
- timeFrame
- 12 weeks
- description
- Number of comments from participants indicating ease of use of the application.
Secondary outcomes (3)
- measure
- Blood pressure (BP) readings measured daily by the BP monitoring device compared with those BP readings measured at interval clinic visits within the first 12 weeks to determine similar detection of symptoms.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Patients \> 18 years of age Patients planning to start treatment with cabozantinib therapy for renal cancer. Technology requirement: The patient will need to have home wireless internet access for use of the software and technology in this study. The patient will need to already have or be willing to set up a Duke MyChart account. Exclusion Criteria: Non-English Speaking. Any patient who is not able to comprehend and operate the technology at the discretion of the enrolling provider.
References
Publications (0)
Data not yet available
No reference posted for this study.